Start of Day Message
January 29, 2026
LONDON, 29 Jan. 2026 (GLOBE NEWSWIRE) — This is the Start of Day Message for GlobeNewswire. GlobeNewswire is operated by Notified and is designated by the FCA as an approved
Central Wyoming College Announces Fall 2025 President’s and Dean’s Lists
January 29, 2026
Riverton, Wyoming, Jan. 28, 2026 (GLOBE NEWSWIRE) — Central Wyoming College (CWC) recognizes the academic achievements of its students by announcing those named to the President’s List and Dean’s List
Callan Family Office Crosses $10 Billion in Assets Under Management
January 28, 2026
PHILADELPHIA, Jan. 28, 2026 (GLOBE NEWSWIRE) — Callan Family Office, a registered investment advisor serving ultra-high-net-worth families, family offices, foundations, and endowments across the United States, today announced that it
Atico Reports Multiple Higher-Grade Intercepts up to 10.20m of 6.26% Cu, 8.50 g/t Au and 10.0m of 6.77% Cu, 3.39 g/t Au and Continues to Extend the Ore Body at El Roble Mine in Colombia
January 28, 2026
VANCOUVER, British Columbia, Jan. 28, 2026 (GLOBE NEWSWIRE) — Atico Mining Corporation (TSX.V: ATY | OTCID: ATCMF) (“Atico” or the “Company”) is pleased to announce positive results from 21 drill
Global expansion of Idorsia’s QUVIVIQ continues with EMS partnership for Latin America
January 28, 2026
Ad hoc announcement pursuant to Art. 53 LR Regulatory dossier to obtain marketing authorization for QUVIVIQ has been submitted to ANVISA in Brazil Allschwil, Switzerland – January 28, 2026Idorsia Ltd
Aben Gold Closes Private Placement Financing
January 28, 2026
Not for distribution to U.S. newswire services or for dissemination in the United States Vancouver, BC, Jan. 27, 2026 (GLOBE NEWSWIRE) — Aben Gold Corp. (TSX-V: ABM) (OTCID: ABNAF) (Frankfurt: ML1) (“Aben” or
Stewart's Brave Battle Against Leukemia: A Family's Journey of Hope and Science
January 27, 2026
Charleston, SC, Jan. 27, 2026 (GLOBE NEWSWIRE) — In a world before cellphones and the internet, young Stewart faces a daunting diagnosis of Acute Lymphocytic Leukemia, labeled by doctors at
Aclaris Therapeutics’ Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)
January 27, 2026
– ATI-2138 Outperforms Ritlecitinib in Reversal Model of Alopecia Universalis, the Most Severe AA Phenotype – WAYNE, Pa., Jan. 27, 2026 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a
Open Invention Network Unveils “OIN 2.0” to Enable the Next Era of Open Source Patent Protection
January 27, 2026
DURHAM, N.C., Jan. 27, 2026 (GLOBE NEWSWIRE) — Since its founding in 2005, Open Invention Network (OIN) has been the only organization focused on mitigating patent risk in open source
Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment
January 26, 2026
NEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on use of Ryoncil® (remestemcel-L-rknd)
CORRECTION – Obagi Medical and Platinum Dermatology Partners Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
January 26, 2026
In a release issued under the same headline earlier today by Waldencast plc (NASDAQ: WALD), please note that the quote by Michael Pennington in paragraph 3 was incorrect. The corrected
UK Engineering and Manufacturing SMEs Invited to Take Part in Enginuity’s Second SME Snapshot Survey
January 26, 2026
LONDON, Jan. 26, 2026 (GLOBE NEWSWIRE) — Small and medium-sized enterprises (SMEs) across the UK’s engineering and manufacturing sector, are being given a chance to share their experiences, priorities, and
WealthW-Group Announces Governance-Centered Strategy for Digital Asset Operations
January 26, 2026
New York, USA, Jan. 26, 2026 (GLOBE NEWSWIRE) — WealthW-Group today announced the implementation of a governance-focused operational strategy for its activities within the digital asset sector. The firm’s approach
FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease under Priority Review
January 25, 2026
If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease FDA action date
Washington, D.C. Auto Show Closed Today Due to Snowstorm and Dangerous Driving Conditions
January 25, 2026
Washington, D.C. Auto Show, Jan. 25, 2026 (GLOBE NEWSWIRE) — MEDIA ALERT FOR IMMEDIATE RELEASEJanuary 25, 2026 Due to the snowstorm and dangerous driving conditions, the Washington, D.C. Auto Show